Physician, scientist, patient, advocate: Glenn Pierce inhabits all four roles, and seems the physical embodiment of the translational impulse, driven by his own experiences coping with severe hemophilia to advance the science – and the policy – he hopes will eventually cure this condition for patients across the globe.
While other kids enjoyed carefree childhoods, Glenn spent much of his early years in the hospital, recovering from bleeding episodes associated with the hemophilia A with which he was born. From this experience was born a passion to cure hemophilia, a commitment he memorialized in writing when he was ten, during one of the many hospital stays.
Glenn, a native of Cleveland, attended college at Case Western, and stayed at Case for his MD/PhD, then went to Washington University in St. Louis for additional training in laboratory medicine and hematology, though he explicitly steered clear of hemophilia professionally, thinking at the time this might be uncomfortably close to home; on the side, however, he volunteered for hemophilia organizations, and became increasingly involved with the community.
After a series of industry roles with increasing responsibility, Glenn decided he wanted to unite his personal and professional passions, and started to work at the interface, leveraging his deep personal commitment and an increasingly large team of experts; in a sense, he became a hemophilia entrepreneur, working with his selected colleagues to drive the science forward in a range of companies that would include Bayer and Biogen.
Today, Glenn drives innovation as an entrepreneur-in-residence at Third Rock Ventures, where he’s foundationally involved with companies such as the liver-focused Ambys Medicines (note: David’s firm, TVI, is an investor). He is also actively involved with the World Federation of Hemophilia, as he seeks to improve the lives of patients with hemophilia around the globe.